Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doxorubicin Hydrochloride

FDA-approved product (injectable, injection), marketed as Adriamycin Pfs, Doxil (Liposomal), Doxorubicin Hydrochloride and 2 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Doxorubicin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute myelomonocytic leukemia
  • Bone sarcoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Carcinoma
  • Childhood epithelioid sarcoma
  • Classic Hodgkin lymphoma
  • Epithelioid sarcoma
  • Heart failure
  • HER2 Positive Breast Carcinoma
  • Hodgkins lymphoma
  • Kaposi's sarcoma
  • Malignant epithelial tumor of ovary
  • Multiple myeloma
  • and 9 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anthracyclines and related substances
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 0 of 1 lab record
Open Doxorubicin Hydrochloride in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doxorubicin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer

    NCT00006433 · start 2000-01

    Registered record
    Registry ID
    NCT00006433
    Conditions
    Breast Cancer
    Interventions
    Doxil; heat treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2000-01
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDoxil; heat treatment
    PhasePhase 2
    Registry statusUnknown

  • Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin

    NCT00022178 · start 1998-12

    Registered record
    Registry ID
    NCT00022178
    Conditions
    Carcinoma of Unknown Primary
    Interventions
    cisplatin; cyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride; fluorouracil; vincristine sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    1998-12
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma of Unknown Primary
    Interventioncisplatin; cyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride +2 more
    PhasePhase 3
    Registry statusUnknown

  • Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer

    NCT00003035 · start 1997-03

    Registered record
    Registry ID
    NCT00003035
    Conditions
    Breast Cancer
    Interventions
    filgrastim; doxorubicin hydrochloride; paclitaxel; tamoxifen citrate; surgical procedure; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-03
    Completion
    2001-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionfilgrastim; doxorubicin hydrochloride; paclitaxel; tamoxifen citrate +2 more
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer

    NCT00002919 · start 1996-11

    Registered record
    Registry ID
    NCT00002919
    Conditions
    Bladder Cancer
    Interventions
    filgrastim; cisplatin; doxorubicin hydrochloride; methotrexate; vinblastine sulfate; conventional surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1996-11
    Completion
    2003-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer
    Interventionfilgrastim; cisplatin; doxorubicin hydrochloride; methotrexate +2 more
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy in Treating Children With Lymphoma

    NCT00002590 · start 1994-07

    Registered record
    Registry ID
    NCT00002590
    Conditions
    Lymphoma
    Interventions
    filgrastim; cyclophosphamide; cytarabine; daunorubicin hydrochloride; doxorubicin hydrochloride; etoposide; leucovorin calcium; methotrexate; pegaspargase; prednisone; thioguanine; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1994-07
    Completion
    2007-03
    Enrolment
    221

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionfilgrastim; cyclophosphamide; cytarabine; daunorubicin hydrochloride +9 more
    PhasePhase 2
    Registry statusCompleted